1
|
El-Khawaldeh R, Guy M, Bork F, Taherimakhsousi N, Jones KN, Hawkins JM, Han L, Pritchard RP, Cole BA, Monfette S, Hein JE. Keeping an "eye" on the experiment: computer vision for real-time monitoring and control. Chem Sci 2024; 15:1271-1282. [PMID: 38274057 PMCID: PMC10806693 DOI: 10.1039/d3sc05491h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 11/24/2023] [Indexed: 01/27/2024] Open
Abstract
This work presents a generalizable computer vision (CV) and machine learning model that is used for automated real-time monitoring and control of a diverse array of workup processes. Our system simultaneously monitors multiple physical outputs (e.g., liquid level, homogeneity, turbidity, solid, residue, and color), offering a method for rapid data acquisition and deeper analysis from multiple visual cues. We demonstrate a single platform (consisting of CV, machine learning, real-time monitoring techniques, and flexible hardware) to monitor and control vision-based experimental techniques, including solvent exchange distillation, antisolvent crystallization, evaporative crystallization, cooling crystallization, solid-liquid mixing, and liquid-liquid extraction. Both qualitative (video capturing) and quantitative data (visual outputs measurement) were obtained which provided a method for data cross-validation. Our CV model's ease of use, generalizability, and non-invasiveness make it an appealing complementary option to in situ and real-time analytical monitoring tools and mathematical modeling. Additionally, our platform is integrated with Mettler-Toledo's iControl software, which acts as a centralized system for real-time data collection, visualization, and storage. With consistent data representation and infrastructure, we were able to efficiently transfer the technology and reproduce results between different labs. This ability to easily monitor and respond to the dynamic situational changes of the experiments is pivotal to enabling future flexible automation workflows.
Collapse
Affiliation(s)
- Rama El-Khawaldeh
- Department of Chemistry, University of British Columba Vancouver BC Canada
| | - Mason Guy
- Department of Chemistry, University of British Columba Vancouver BC Canada
| | - Finn Bork
- Department of Chemistry, University of British Columba Vancouver BC Canada
| | | | - Kris N Jones
- Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA
| | - Joel M Hawkins
- Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA
| | - Lu Han
- Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA
| | - Robert P Pritchard
- Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA
| | - Blaine A Cole
- Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA
| | - Sebastien Monfette
- Pfizer Worldwide Chemical Research and Development, Pfizer Inc. Groton Connecticut 06340 USA
| | - Jason E Hein
- Department of Chemistry, University of British Columba Vancouver BC Canada
- Acceleration Consortium, University of Toronto Toronto ON Canada
- Department of Chemistry, University of Bergen Bergen Norway
| |
Collapse
|
2
|
Baldwin A, Cabral S, Jones KN, Kohrt JT, Limberakis C, Liu Y, Magano J, Monfette S, Nematalla A, Ovaska S, Piotrowski DW, Piper JL, Raggon JW, Thuma BA, Wei L. Route Optimization of the Non-covalent Modulator of Hemoglobin PF-07059013 for the Treatment of Sickle Cell Disease, Part I: From Discovery Synthesis to First Kilogram-Scale Manufacture. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Affiliation(s)
- Aaron Baldwin
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Shawn Cabral
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Kris N. Jones
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jeffrey T. Kohrt
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Chris Limberakis
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Yiyang Liu
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Javier Magano
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Sebastien Monfette
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Asaad Nematalla
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Sami Ovaska
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - David W. Piotrowski
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jared L. Piper
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jeffrey W. Raggon
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Benjamin A. Thuma
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Liuqing Wei
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| |
Collapse
|
3
|
Duan S, Widlicka DW, Burns MP, Kumar R, Hotham I, Desrosiers JN, Bowles P, Jones KN, Nicholson LD, Buetti-Weekly MT, Han L, Steflik J, Hansen E, Hayward CM, Strohmeyer H, Monfette S, Sutton SC, Morris C. Application of Biocatalytic Reductive Amination for the Synthesis of a Key Intermediate to a CDK 2/4/6 Inhibitor. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00255] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Shengquan Duan
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Daniel W. Widlicka
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Michael P. Burns
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Rajesh Kumar
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Ian Hotham
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Jean-Nicolas Desrosiers
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Paul Bowles
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Kris N. Jones
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Lindsay D. Nicholson
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Michele T. Buetti-Weekly
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Lu Han
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Jeremy Steflik
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Eric Hansen
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Cheryl M. Hayward
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Holly Strohmeyer
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Sébastien Monfette
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Scott C. Sutton
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| | - Christopher Morris
- Chemical and Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Groton, Connecticut 06340, United States
| |
Collapse
|
4
|
Goetz AE, Becirovic H, Blasberg F, Chen B, Clarke HJ, Colombo M, Daddario P, Damon DB, Depretz C, Dumond YR, Grilli MD, Han L, Houck TL, Johnson AM, Jones KN, Jung J, Leeman M, Liu F, Lu CV, Mangual EJ, Nelson JD, Puchlopek-Dermenci ALA, Ruggeri SG, Simonds PA, Sitter B, Virtue DE, Wang S, Yu L, Yu T. Large-Scale Cyclopropanation of Butyl Acrylate with Difluorocarbene and Classical Resolution of a Key Fluorinated Building Block. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00171] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Adam E. Goetz
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Husein Becirovic
- Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Florian Blasberg
- AMRI, Euticals GmbH, Industriepark Höchst D569, 65926 Frankfurt am Main, Germany
| | - Bo Chen
- Porton R&D Center, No. 1299 Ziyue Rd, Zizhu Science Park, Minhang District, Shanghai, China
| | - Hugh J. Clarke
- Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | | | - Pedro Daddario
- Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - David B. Damon
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Christelle Depretz
- AMRI, Euticals S.A.S., Zone Industrielle de Laville, 47240 Bon-Encontre, France
| | - Yves R. Dumond
- AMRI, Euticals S.A.S., Zone Industrielle de Laville, 47240 Bon-Encontre, France
| | | | - Lu Han
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tim L. Houck
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Amber M. Johnson
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kris N. Jones
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jörg Jung
- AMRI, Euticals GmbH, Industriepark Höchst D569, 65926 Frankfurt am Main, Germany
| | - Michel Leeman
- Symeres BV, Kadijk 3, 9747 AT Groningen, The Netherlands
| | - Fangfang Liu
- Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cuong V. Lu
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Emilio J. Mangual
- Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jade D. Nelson
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Angela L. A. Puchlopek-Dermenci
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Sally Gut Ruggeri
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Paul A. Simonds
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Barbara Sitter
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Daniel E. Virtue
- Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Shuguang Wang
- Porton R&D Center, No. 1299 Ziyue Rd, Zizhu Science Park, Minhang District, Shanghai, China
| | - Lixin Yu
- Porton R&D Center, No. 1299 Ziyue Rd, Zizhu Science Park, Minhang District, Shanghai, China
| | - Tao Yu
- Porton R&D Center, No. 1299 Ziyue Rd, Zizhu Science Park, Minhang District, Shanghai, China
| |
Collapse
|
5
|
Brown MS, Caporello MA, Goetz AE, Johnson AM, Jones KN, Knopf KM, Kulkarni SA, Lee T, Li B, Lu CV, Magano J, Puchlopek-Dermenci ALA, Reyes GP, Ruggeri SG, Wei L, Weisenburger GA, Wisdom RA, Zhang M. Streamlined Synthesis of a Bicyclic Amine Moiety Using an Enzymatic Amidation and Identification of a Novel Solid Form. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00120] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Maria S. Brown
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Michaella A. Caporello
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Adam E. Goetz
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Amber M. Johnson
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kris N. Jones
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kevin M. Knopf
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Samir A. Kulkarni
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Taegyo Lee
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Bryan Li
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cuong V. Lu
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Javier Magano
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Angela L. A. Puchlopek-Dermenci
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Giselle P. Reyes
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Sally Gut Ruggeri
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Lulin Wei
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Gerald A. Weisenburger
- Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Richard A. Wisdom
- Euticals GmbH, Industriepark
Höchst, D 569, 65926 Frankfurt am Main, Germany
| | - Mengtan Zhang
- Analytical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
6
|
Connor CG, DeForest JC, Dietrich P, Do NM, Doyle KM, Eisenbeis S, Greenberg E, Griffin SH, Jones BP, Jones KN, Karmilowicz M, Kumar R, Lewis CA, McInturff EL, McWilliams JC, Mehta R, Nguyen BD, Rane AM, Samas B, Sitter BJ, Ward HW, Webster ME. Development of a Nitrene-Type Rearrangement for the Commercial Route of the JAK1 Inhibitor Abrocitinib. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00366] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
7
|
Moyer AM, Boughey JC, Kalari KR, Suman VJ, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Sinnwell JP, Carlson EE, Dockter TJ, Jones KN, Felten SJ, Conners AL, Wieben ED, Ingle JN, Wang L, Weinshilboum RM, Visscher DW, Goetz MP. Abstract P4-04-05: Differential mRNA expression patterns in breast tumors with high vs. low quantity of stromal tumor–Infiltrating lymphocytes. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-04-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor-infiltrating lymphocytes (TIL) have prognostic and potentially predictive significance in the (neo)adjuvant treatment of high-risk breast cancer. However, quantitative TIL measurement is not routinely performed. It is unclear why some tumors attract large quantities of TIL while others do not. We sought to confirm the association between TIL and pathologic complete response rate (pCR) and to further use next generation sequencing (NGS) to identify genes and gene pathways associated with the presence/absence of TIL.
Methods: We studied 140 women with high risk stage I-III breast cancer, enrolled in the Breast Cancer Genome Guided Therapy Study (BEAUTY), obtaining serial biopsies for DNA/RNA sequencing and MRI imaging to assess response to neoadjuvant chemotherapy (NAC) with taxane (+/- trastuzumab+/-pertuzumab for HER2+ disease) followed by AC or (F)EC. Diagnostic pre-NAC core needle biopsies and surgical resection specimens post-NAC were available from 110 patients. Stromal TIL were semi-quantitated on a scale of 1-4 (with 1: ≤10/hpf, 2: subtle infiltrate >10/hpf, 3: moderate infiltrate readily visible at low power magnification, 4: dense infiltrate with innumerable lymphocytes). For this analysis, low TIL was defined as scores of 1-2 vs. high defined as 3-4. Using pre-NAC biopsies, RNAseq was performed using the Illumina HiSeq2000 and the Mayo Analysis Pipeline for RNAseq (MAP-Rseq) for quality control, sequence alignment, and gene counts. The quantity of TIL was associated with transcripts across the transcriptome after conditional quantile normalization. Differentially expressed genes were obtained using EdgeR analysis, using a false discovery rate of 0.05, and pathways were evaluated using GAGE methods.
Results: The pCR and residual cancer burden (RCB)-0/I rates by stromal TIL status within each molecular subtype are presented in the table. A diverse spectrum of 1344 genes with differential expression between tumors with high vs. low stromal TIL was identified. The genes with >2.0-fold change (FC) and p<1e-09 included S100A7 (4.49 FC), LCN2 (2.48 FC), and ART3 (2.82 FC) (genes known to be involved in immune regulation), as well as TDRD1 (2.71 FC) (a gene related to ERG [ETS-related gene] expression). In addition, the "regulation of actin cytoskeleton" pathway was upregulated in tumors with high TIL, while the "Hedgehog signaling" and "Wnt signaling" pathways were downregulated.
Molecular SubtypeStromal TILspCR rate n (%)RCB-0/I rateLuminal AHigh------Luminal ALow0/9 (0%)0/9 (0%)Luminal BHigh1/9 (11.1%)1/8 (12.5%)Luminal BLow3/24 (12.5%)6/23 (26.1%)ER+/HER2+High3/9 (33.3%)4/9 (44.4%)ER+/HER2+Low1/6 (16.7%)1/6 (16.7%)ER-/HER2+High8/9 (88.9%)7/7 (100%)ER-/HER2+Low4/8 (50.0%)6/8 (75.0%)Triple NegativeHigh10/19 (52.6%)13/19 (68.4%)Triple NegativeLow7/14 (50.0%)9/13 (69.2%)
Conclusions: We identified genes and gene pathways associated with high TIL expression in breast tumors prior to NAC that provide insight into the interactions between TIL and tumors. TIL can be easily semi-quantitated on H&E and along with these novel biomarkers, may contribute to the personalization of breast cancer therapy.
Citation Format: Moyer AM, Boughey JC, Kalari KR, Suman VJ, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Sinnwell JP, Carlson EE, Dockter TJ, Jones KN, Felten SJ, Conners AL, Wieben ED, Ingle JN, Wang L, Weinshilboum RM, Visscher DW, Goetz MP. Differential mRNA expression patterns in breast tumors with high vs. low quantity of stromal tumor–Infiltrating lymphocytes. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-04-05.
Collapse
Affiliation(s)
- AM Moyer
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JC Boughey
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KR Kalari
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - VJ Suman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SA McLaughlin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - A Moreno-Aspitia
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Northfelt
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - RJ Gray
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JP Sinnwell
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - EE Carlson
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - TJ Dockter
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KN Jones
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SJ Felten
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - AL Conners
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - ED Wieben
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JN Ingle
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - L Wang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - RM Weinshilboum
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Visscher
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - MP Goetz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
8
|
Boughey JC, Kalari KR, Suman VJ, McLaughlin SA, Moreno Aspitia A, Moyer AM, Northfelt DW, Gray RJ, Vedell PT, Tang X, Dockter TJ, Jones KN, Felten SJ, Conners AL, Hart SN, Visscher DW, Wieben ED, Ingle JN, Hartman AR, Timms K, Elkin E, Jones J, Wang L, Weinshilboum RW, Goetz MP. Abstract P3-07-29: Role of germline BRCA status and tumor homologous recombination (HR) deficiency in response to neoadjuvant weekly paclitaxel followed by anthracycline-based chemotherapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Both HR deficiency and BRCA mutation status predict response to platinum-based therapy and BRCA mutation status predicts docetaxel resistance. However, the association of either biomarker with response to the individual elements of either AC or taxanes (T) is unknown since T is commonly given concomitantly with or after anthracyclines (A). We evaluated the association of HRD and BRCA mutation status with response to neoadjuvant weekly T followed by AC or (F)EC in high-risk breast cancer.
Methods: We studied 140 high risk Stage I-III breast cancer patients (pts), enrolled in the breast cancer genome guided therapy study (BEAUTY), obtaining biopsies for DNA/RNA sequencing and MRI imaging to assess response to neoadjuvant weekly T (+trastuzumab+/-pertuzumab for HER2+ disease) followed by AC or (F)EC. Germline BRCA status and HR status of tumor samples (Myriad laboratories) were obtained. HR deficient tumor was defined as HRD score ≥42 or BRCA mutation. MRI response by changes in tumor size after 12 weeks of T was classified by WHO criteria. pCR was defined as ypT0/Tis ypN0. Both MRI response after T and pCR (after T and AC) were examined in terms of germline BRCA mutation (gBRCAmut vs. gBRCAwt) and tumor HR deficiency.
Results: Of 140 pts enrolled, 8 withdrew consent and 2 carboplatin treated pts were excluded. Germline data were available for 124/130 pts. 12 patients had BRCA deleterious germline mutations (4 BRCA1, 8 BRCA2). MRI partial (PR)/complete response (CR) rate to T was 47.3% (95% CI: 37.8-57.0%) in the BRCAwt group and 66.7% (95% CI: 34.9-90.1%) in the BRCAmut group. No MRI CR's were observed in BRCA1 mut pts. In contrast, pCR rate was 50% in the 12 gBRCAmut pts (95% CI: 21.1-78.9%) and 31.3% in the 112 gBRCAwt pts (95% CI: 22.8-40.7%). HR deficiency status has thus far been determined for 74 pts: 26 pts have HD deficient tumors: 18 TNBC, 5 Luminal B, 2 ER-/HER2+; and 1 ER+/HER2+. Determination of HR deficiency is ongoing and will be reported for the full cohort in terms of 12 week MRI response to T and pCR to T+AC.
HR deficientMolecular Subtypeyes (%)no (%)TBD (%)Luminal A0/112/11 (18.2)9/11 (81.8)Luminal B5/37 (13.5)13/37 (35.1)19/37 (51.3)Luminal NOS0/21/2 (50)1/2 (50)ER+/Her2+1/17 (5.8)14/17 (82.4)2/17 (11.8)ER-/Her2+2/20 (10)11/20 (55)7/20 (35)Triple Negative18/43 (41.9)6/43 (18.6)17/43 (39.5)germline BRCA statusMRI partial response after T (%)MRI complete response after T (%)pCR after T&AC (%)BRCA11/4 (25)0/42/4 (50)BRCA25/8 (62.5)2/8 (25)4/8 (50)BRCAwt35/112 (31.3)18/112 (16.1)35/112 (31.3)
Conclusion: In the setting of neoadjuvant weekly T followed by AC, pCR rates were non-significantly higher in pts with BRCA1 mutations. While we observed no overall association between BRCA mutation status and response rates to taxanes; nearly all MRI responses to taxanes (partial and complete) were observed in the BRCA2 group. Prospective studies are needed to validate these findings and to determine whether BRCA status can be used to select therapy. HR deficiency is uncommon in luminal A and HER2+, frequent in TNBC, and the association of HRD with both MRI response to taxanes and pCR will be reported at the meeting.
Citation Format: Boughey JC, Kalari KR, Suman VJ, McLaughlin SA, Moreno Aspitia A, Moyer AM, Northfelt DW, Gray RJ, Vedell PT, Tang X, Dockter TJ, Jones KN, Felten SJ, Conners AL, Hart SN, Visscher DW, Wieben ED, Ingle JN, Hartman A-R, Timms K, Elkin E, Jones J, Wang L, Weinshilboum RW, Goetz MP. Role of germline BRCA status and tumor homologous recombination (HR) deficiency in response to neoadjuvant weekly paclitaxel followed by anthracycline-based chemotherapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-29.
Collapse
Affiliation(s)
- JC Boughey
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - KR Kalari
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - VJ Suman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - SA McLaughlin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - A Moreno Aspitia
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - AM Moyer
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - DW Northfelt
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - RJ Gray
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - PT Vedell
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - X Tang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - TJ Dockter
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - KN Jones
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - SJ Felten
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - AL Conners
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - SN Hart
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - DW Visscher
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - ED Wieben
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - JN Ingle
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - A-R Hartman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - K Timms
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - E Elkin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - J Jones
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - L Wang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - RW Weinshilboum
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - MP Goetz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| |
Collapse
|
9
|
Yu J, Qin B, Boughey JC, Moyer AM, Visscher DW, Sinnwell JP, Yin P, Thompson KJ, Docter TJ, Kalari KR, Suman VJ, Wieben ED, Felten SJ, Conners AL, Jones KN, McLaughlin SA, Copland JA III, Moreno Aspitia A, Northfelt DW, Gray RJ, Ingle JN, Lou Z, Weinshilboum R, Goetz MP, Wang L. Abstract P3-07-51: Regulation of DNA methyltransferases via TRAF6 determines breast cancer response to decitabine. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-51] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumorigenesis involves both genetic and epigenetic changes. Epigenetic alterations are reversible and are promising cancer therapeutic targets. Decitabine (5-aza-2'-deoxycytidine), a DNA methyltransferase inhibitor, is FDA approved for hematological malignancies. However, the effect of decitabine in breast cancer is not completely understood. Previous reports indicated that one decitabine mechanism involves regulation of protein levels for DNMT1, the major DNA methyltransferase that methylates hemimethylated CpG di-nucleotides in DNA. However, the E3 ligase involved in this process has not been identified. Whether decitabine also regulates DNMT3A and 3B in a similar fashion remains unclear. Therefore, our goals were to 1) understand mechanisms underlying decitabine action, 2) test the antitumor activity of decitabine in breast cancer models and 3) identify biomarkers associated with response to decitabine.
Methods and Results: Western blots of breast cancer cell lines showed that DNMT1, DNMT3A, and DNMT3B protein levels decreased following decitabine treatment without a reduction in mRNA levels. Bioinformatic analysis of DNA methyltransferase sequences revealed a potential TRAF6 binding motif, and the interaction with TRAF6 (TNF receptor-associated factor 6) was confirmed by IP. TRAF6 functions as an E3 ligase. To determine whether TRAF6 might be the E3 ligase responsible for the degradation of DNMTs after decitabine treatment, we knocked down TRAF6 by RNA interference or knocked out the TRAF6 gene by CRISPR/Cas9. Down regulation of TRAF6 attenuated DNMT ubiquitination and increased DNMT protein levels, suggesting that TRAF6 might mediate proteasome-dependent degradation of all three DNMTs. This was further confirmed by reconstituting the knockout cells with WT and a TRAF6-C70A mutant, followed by assessing DNMT protein levels. Global DNA methylation was also increased after TRAF6 depletion and was confirmed in TRAF6 knock out cells in which DNMT levels were unaffected by decitabine. Cell cytotoxicity and colony forming assays showed that TRAF6 knockout cells were resistant to decitabine, suggesting that a major decitabine mechanism of action is through the regulation of TRAF6 which, in turn, degrades DNMTs, leading to decreased global methylation. Finally, decitabine significantly induced TRAF6 at both mRNA and protein levels, a process that might create positive feedback leading to increased degradation of DNMT proteins upon decitabine treatment. Based on these results, we further hypothesized that levels of the three DNMTs might influence decitabine response. Using 18 breast cancer patient derived xenograft (PDX) models, we found a wide range of DNMT protein levels regardless of ER/HER2 status. DNMT levels in the PDX models were directly associated with sensitivity to decitabine treatment, confirming our hypothesis.
Conclusion: Our data showed that decitabine might be an effective agent for treating breast cancer and revealed a novel mechanism underlying decitabine treatment. Baseline DNMT protein levels may serve as a biomarker for predicting decitabine drug response.
Citation Format: Yu J, Qin B, Boughey JC, Moyer AM, Visscher DW, Sinnwell JP, Yin P, Thompson KJ, Docter TJ, Kalari KR, Suman VJ, Wieben ED, Felten SJ, Conners AL, Jones KN, McLaughlin SA, Copland JA III, Moreno Aspitia A, Northfelt DW, Gray RJ, Ingle JN, Lou Z, Weinshilboum R, Goetz MP, Wang L. Regulation of DNA methyltransferases via TRAF6 determines breast cancer response to decitabine. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-51.
Collapse
Affiliation(s)
- J Yu
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - B Qin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JC Boughey
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - AM Moyer
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Visscher
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JP Sinnwell
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - P Yin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KJ Thompson
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - TJ Docter
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KR Kalari
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - VJ Suman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - ED Wieben
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SJ Felten
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - AL Conners
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KN Jones
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SA McLaughlin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - III Copland JA
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - A Moreno Aspitia
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Northfelt
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - RJ Gray
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JN Ingle
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - Z Lou
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - R Weinshilboum
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - MP Goetz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - L Wang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
10
|
Bowles P, Brenek SJ, Caron S, Do NM, Drexler MT, Duan S, Dubé P, Hansen EC, Jones BP, Jones KN, Ljubicic TA, Makowski TW, Mustakis J, Nelson JD, Olivier M, Peng Z, Perfect HH, Place DW, Ragan JA, Salisbury JJ, Stanchina CL, Vanderplas BC, Webster ME, Weekly RM. Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin. Org Process Res Dev 2014. [DOI: 10.1021/op4002802] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Paul Bowles
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Steven J. Brenek
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Stéphane Caron
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Nga M. Do
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Michele T. Drexler
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Shengquan Duan
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Pascal Dubé
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Eric C. Hansen
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Brian P. Jones
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kris N. Jones
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tomislav A. Ljubicic
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Teresa W. Makowski
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jason Mustakis
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jade D. Nelson
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mark Olivier
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Zhihui Peng
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Hahdi H. Perfect
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - David W. Place
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - John A. Ragan
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - John J. Salisbury
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Corey L. Stanchina
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Brian C. Vanderplas
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mark E. Webster
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - R. Matt Weekly
- Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
11
|
Goetz MP, Boughey JC, Kalari KR, Eckel-Passow J, Suman VJ, Sicotte H, Hart SN, Moyer AM, Visscher DW, Yu J, Gao B, Sinnwell JP, Mahoney DW, Barman P, Vedell P, Tang X, Thompson K, Dockter TJ, Jones KN, Conners AL, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Wieben ED, Farrugia G, Schultz C, Ingle JN, Wang L, Weinshilboum RW. Abstract P1-08-10: Integration of next generation sequencing (NGS) and patient derived xenografts (PDX) to identify novel markers of paclitaxel (T) response in the breast cancer genome guided therapy study (BEAUTY). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Based upon the association between pathologic response and disease free survival, the neoadjuvant setting is increasingly being used for drug development. NGS has identified unique and recurrent genetic alterations in breast cancer (BC) that are potentially targetable; however, the clinical implications are mostly unknown. We developed a prospective neoadjuvant study (BEAUTY) in high risk BC patients (pts) using weekly T followed by anthracycline-based chemo wherein percutaneous tumor biopsies (PTB) are obtained before/during/after chemo for NGS and PDX. Our goal is to identify novel biomarkers/pathways and develop PDX to test new therapeutic approaches.
Methods: Pts underwent PTB at baseline and after 12 wks of T. Response to T was defined based upon 12 week Ki-67: responder (<15%) vs non-responder (≥15%). Pts with histologic response and absence of invasive BC at 12 wks were classified as responders. NGS was performed using PTB/blood DNA (exome) and PTB (RNA seq). MRI response was classified using RECIST criteria. NGS data were used to identify somatic copy number variants (cnvs) and expressed single nucleotide variants (eSNVs). Non-SCID mice (estrogen supplemented) were implanted ≤ 30 minutes with PTB samples.
Results: Of the first 78 pts, 44 have completed T. Here we focus on 18 pts with either triple negative or luminal B BC. Clinical characteristics according to Ki-67 response are shown in Table 1. Comparison of genomic alterations in BEAUTY pts with TCGA identified a greater overlap with copy number gains (73%) compared to deletions (40%), along with similar observations of mutations in TP53, PTEN, RYR2, and AKT1 genes. Association analysis of CNVs and eSNVs between responders/non-responders identified 33 genes (predominantly located in chromosomes 1, 8, 13) and 580 eSNVs (corresponding to 497 genes) with a p < 0.05. Differential gene expression (DGE) analysis of responders/non-responders identified 198 genes with a p-value < 0.05. Integrated analysis of 539 genes (CNVs, eSNVs and DGE) identified pathways such as TGF-beta, Jak-Stat, WNT and NOTCH signalling. PDX take rate was 44% [triple negative (6/10); Luminal B (2/8)]. PDX growth rate was significantly associated with clinical baseline Ki-67 (p = 0.00014).
Conclusion: This is the first prospective study to demonstrate the feasibility of using PTB to obtain both NGS data and PDX in the neoadjuvant setting. PDX take rate is associated with BC subtype and baseline Ki-67. Studies are ongoing to 1) validate genes/pathways associated with treatment response in subsequent BEAUTY pts; 2) genomically characterize and assess PDX in vivo response to T and 3) Use NGS data to prioritize new drugs/drug combinations in PDX.
Funded by Mayo Clinic Center for Individualized Medicine and MC Cancer Center.
Clinical CharacteristicsOverallResponders: 12 week Ki-67 < 15% (n = 9)Non-Responders: 12 week Ki-67 ≥ 15% (n = 9)Median Age495345T stage T2/T314 (78%)7 (78%)7 (78%)Node Positive8 (44%)4 (44%)4 (44%)Triple negative10 (56%)6 (67%)4 (44%)Luminal B8 (44%)3 (33%)5 (56%)Ki-67 after 12 Weeks of T Median 5% (0-11%)Median 35% (17-60%)Complete/Partial MRI Response after T 6 (67%)2 (22%)
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-10.
Collapse
Affiliation(s)
- MP Goetz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JC Boughey
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KR Kalari
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - J Eckel-Passow
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - VJ Suman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - H Sicotte
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SN Hart
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - AM Moyer
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Visscher
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - J Yu
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - B Gao
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JP Sinnwell
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Mahoney
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - P Barman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - P Vedell
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - X Tang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - K Thompson
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - TJ Dockter
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KN Jones
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - AL Conners
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SA McLaughlin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - A Moreno-Aspitia
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Northfelt
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - RJ Gray
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - ED Wieben
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - G Farrugia
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - C Schultz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JN Ingle
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - L Wang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - RW Weinshilboum
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
12
|
Ide ND, Ragan JA, Bellavance G, Brenek SJ, Cordi EM, Jensen GO, Jones KN, LaFrance D, Leeman KR, Letendre LJ, Place D, Stanchina CL, Sluggett GW, Strohmeyer H, Blunt J, Meldrum K, Taylor S, Byrne C, Lynch D, Mullane S, O’Sullivan MM, Whelan M. Synthesis of Filibuvir. Part III. Development of a Process for the Reductive Coupling of an Aldehyde and a β-Keto-lactone. Org Process Res Dev 2013. [DOI: 10.1021/op400237j] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Nathan D. Ide
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - John. A. Ragan
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Gabriel Bellavance
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Steve J. Brenek
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Eric M. Cordi
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Grace O. Jensen
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Kris N. Jones
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Danny LaFrance
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Kyle R. Leeman
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Leo J. Letendre
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - David Place
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Corey L. Stanchina
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Gregory W. Sluggett
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Holly Strohmeyer
- Chemical Research
and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, 06340 Connecticut
| | - Jon Blunt
- Chemical Research & Development, Pfizer Process Development Facility, Ramsgate Road, Sandwich, Kent, U.K
| | - Kevin Meldrum
- Chemical Research & Development, Pfizer Process Development Facility, Ramsgate Road, Sandwich, Kent, U.K
| | - Stuart Taylor
- Chemical Research & Development, Pfizer Process Development Facility, Ramsgate Road, Sandwich, Kent, U.K
| | - Ciaran Byrne
- Pfizer Global Supply, Ringaskiddy, Cork County, Ireland
| | - Denis Lynch
- Pfizer Global Supply, Ringaskiddy, Cork County, Ireland
| | | | | | | |
Collapse
|
13
|
Hieken TJ, Fazzio RT, Reynolds C, Jones KN, Ghosh K, Glazebrook KN. Abstract P1-01-22: The utility of axillary ultrasound and sentinel lymph node biopsy in the management of metaplastic breast carcinoma. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-01-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Metaplastic breast carcinoma (MBC) accounts for <5% of all breast malignancies. This entity represents a heterogenous group of tumors in which the adenocarcinomatous element is admixed with one or more neoplastic mesenchymal (spindle, squamous, chondroid, or osseous) elements. Patients typically present with large triple negative tumors and have a poor prognosis. The likelihood of lymph node (LN) involvement has been reported to be low in MBC patients. Due to the paucity of data, we undertook this study to explore the role of axillary ultrasound (US) and sentinel LN biopsy (SLNB) in the management of MBC.
Methods: With IRB approval, we retrospectively identified patients diagnosed with MBC from 2001–2011 from the surgical pathology database. Histopathology and imaging were reviewed. Demographic, treatment and outcome data were obtained by clinical chart review. Data were analyzed using JMP 9.0 software.
Results: We identified 41 women with MBC. Median age was 60 years (range 33–90). Histologic subtypes were spindle cell (46%), mixed adenocarcinoma and mesenchymal elements (20%), squamous cell (17%) chondroid/osseous (10%) and adenosquamous (7%). Tumor stage was T1 (24%), T2 (44%), T3 (12%) and T4 (20%). 26 patients (63%) were treated by mastectomy and 15 (37%) by wide excision. Of the 38 patients who underwent LN surgery (6 low-grade MBC, 32 intermediate/high-grade MBC), 10 (26%) were LN positive. All low-grade MBC patients were LN negative while 10 of 32 intermediate/high-grade MBC patients (31%) had LN metastasis. 22 patients had a preoperative axillary US. 14 patients had a negative axillary US and none had LN metastasis. 4 of 8 patients with suspicious axillary US findings had a preoperative axillary LN fine needle aspiration biopsy (FNAB) and 3 were positive for cancer. These patients proceeded directly to axillary LN dissection (ALND). 24 patients had a SLNB of whom one was SLN positive and underwent completion ALND. LN metastasis was associated with larger tumor size (p = 0.003), higher tumor grade (p = 0.04), angioinvasion (p = 0.07) and abnormal axillary US (p = 0.003). Surviving patients were followed for a mean (median) of 41 (30) months during which 13 (32%) recurred at a median of 6 months (IQR 3–17 months) and 11 (27%) subsequently died of disease. One SLN negative patient developed an axillary recurrence at 8 months, was successfully treated by ALND and is disease-free at 38 months. There were no axillary LN relapses after ALND.
Conclusions: For clinically node-negative MBC patients, our contemporary data series suggests the incidence of occult LN metastasis is sufficiently high to warrant LN staging especially for patients with intermediate and high-grade tumors. This can be accomplished in a minimally invasive fashion with reasonable accuracy (∼97%) with axillary US, FNAB of sonographically suspicious LNs, and SLNB for patients with negative axillary US or FNAB. Axillary LND should be performed for patients with clinically and/or FNAB-positive LN for enhanced disease control.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-22.
Collapse
|
14
|
Jones KN, Mascia B, Waggoner-Fountain L, Pearson RD. Photo quiz. Diagnosis by automated blood analyzer. Clin Infect Dis 2001; 33:1886, 1944-5. [PMID: 11724051 DOI: 10.1086/324095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Affiliation(s)
- K N Jones
- Department of Internal Medicine, Division of Geographic and International Medicine, University of Virginia Health System, Charlottesville, Virginia 22908, USA
| | | | | | | |
Collapse
|
15
|
Jones KN. Reflection: an alternative to nursing models. Prof Nurse 1999; 14:853-5. [PMID: 10603897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
The value of models is currently being challenged by some health-care practitioners. Alternative theoretical underpinnings are required on which to base nursing care. Informal processes which support learning from experience should be formalized to advance nursing practice.
Collapse
Affiliation(s)
- K N Jones
- Chelsea and Westminster NHS Trust, London
| |
Collapse
|
16
|
Brüstle O, Jones KN, Learish RD, Karram K, Choudhary K, Wiestler OD, Duncan ID, McKay RD. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science 1999; 285:754-6. [PMID: 10427001 DOI: 10.1126/science.285.5428.754] [Citation(s) in RCA: 752] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Self-renewing, totipotent embryonic stem (ES) cells may provide a virtually unlimited donor source for transplantation. A protocol that permits the in vitro generation of precursors for oligodendrocytes and astrocytes from ES cells was devised. Transplantation in a rat model of a human myelin disease shows that these ES cell-derived precursors interact with host neurons and efficiently myelinate axons in brain and spinal cord. Thus, ES cells can serve as a valuable source of cell type-specific somatic precursors for neural transplantation.
Collapse
Affiliation(s)
- O Brüstle
- Department of Neuropathology, University of Bonn Medical Center, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Jones KN. RN supply and demand. Hospitals 1988; 62:11. [PMID: 3391541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
18
|
Jones KN. Human resources and trends. J Sterile Serv Manage 1987; 5:52-5. [PMID: 10283166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
I appreciate the opportunity of addressing you on human resource management, some of the issues and some of the trends that face each of us in our roles as managers. Certainly when it comes to managing others regardless of the country, our objectives are virtually the same. All of us want productive work for the payroll dollar we are spending. We want high quality and we want to train and develop employees to the extent necessary in order for our health care organisation to be successful.
Collapse
|
19
|
Jones KN, Steen JA, Collins WE. Predictive validities of several clinical color vision tests for aviation signal light gun performance. Aviat Space Environ Med 1975; 46:660-7. [PMID: 1079455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Scores on the American Optical Company (AOC) test (1965 edition), Dvorine test, Farnsworth Lantern test, Color Threshold Tester, Farnsworth-Munsell 100-Hue test, Farnsworth Panel D-15 test, and Schmidt-Haensch Anomaloscope were obtained from 137 men with color-defective vision and 128 men with normal color vision. The validity of each of these tests in predicting scores on the aviation signal light gun was assessed by using daytime and nighttime administrations of the light gun as the criteria. Two "best sets" of plates from the AOC and Dvorine tests were selected by calculating a multiple regression equation in a stepwise manner with the nighttime and then the daytime administration of the signal light gun test as the criteria. Based on a graphic presentation of the miss and false alarm rates for each test at various possible cut scores, suggestions were made regarding the use of each test and the selection of optimal pass/fail scores.
Collapse
|
20
|
Thackray RI, Jones KN, Touchstone RM. Personality and physiological correlates of performance decrement on a monotonous task requiring sustained attention. Br J Psychol 1974; 65:351-8. [PMID: 4429818 DOI: 10.1111/j.2044-8295.1974.tb01409.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
21
|
Thackray RI TOUCHSTONE RM, Jones KN. Effects of simulated sonic booms on tracking performance and autonomic response. Aerosp Med 1972; 43:13-21. [PMID: 5009154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|